How Much of a Good Thing? What Duration for Interferon Alfa-2b Adjuvant Therapy?
Author:
Affiliation:
1. University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA
2. University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute; Hillman Cancer Center, Pittsburgh, PA
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Link
http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2012.44.9975
Reference25 articles.
1. Clinical and Immunologic Basis of Interferon Therapy in Melanoma
2. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
3. High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190
4. High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801
5. A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Origin and Therapies of Osteosarcoma;Cancers;2022-07-19
2. Cisplatin resistance-related multi-omics differences and the establishment of machine learning models;Journal of Translational Medicine;2022-04-11
3. Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials;Therapeutic Advances in Medical Oncology;2022-01
4. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609;Journal of Clinical Oncology;2020-02-20
5. Current and Emerging Targets in Immunotherapy for Osteosarcoma;Journal of Oncology;2019-01-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3